S Madachi-Yamamoto

Learn More
The hyperosmolarity response, a drug-induced response from the retinal pigment epithelium, was recorded in diabetic retinopathy. The hyperosmolarity response was occasionally abnormal at the pre-retinopathic stage and at the first stage of retinopathy by Scott classification. The response was frequently abnormal at the second and third stages of(More)
The hyperosmolarity response of the standing potential was recorded in retinitis pigmentosa (20 eyes), central (pericentral) retinitis pigmentosa (4 eyes), pigmented paravenous retinochoroidal atrophy (2 eyes), fundus albipunctatus (8 eyes), and Stargardt's disease (or fundus flavimaculatus) (14 eyes). The light peak/dark trough ratio (the L/D ratio) and(More)
Effect of sodium fluorescein was examined on neurite outgrowth from the retinal explants of chick embryos cultured with chicken gizzard extract, containing macromolecules which promote neurite outgrowth. A dose more than 0.5 mg/ml of fluorescein completely prevented the neurite outgrowth from the retinal explants. The minimum dose of toxic effect of(More)
The hyperosmolarity response of the ocular standing potential was examined in 14 eyes of 7 cases of Harada's disease between 8 and 1,341 days after the onset of the disease. The hyperosmolarity response remained normal at the initial stage of the disease when choroiditis, retinal detachment and iridocyclitis were the main manifestations. The hyperosmolarity(More)
The hyperosmolarity response of the ocular standing potential was recorded in unilateral rhegmatogenous retinal detachment (8 eyes) and in the fellow 'healthy' eye (8 eyes). The hyperosmolarity response was greatly suppressed (M-4 SD: M and SD indicate respectively the mean and the standard deviation in normal subjects) in all affected eyes (p less than(More)
The standing potential of the eye is decreased by intravenous administration of hypertonic solutions. This hyperosmolarity-induced response has been recorded in normal subjects by the use of electro-oculography (EOG) in the dark. An intravenous administration of Fructmanit® (1.4 × 103 mOsmol) (150 ∼ 500ml, 2.37 ∼ 9.70ml/kg, 0.08 ∼ 0.36 ml/kg/min) was used(More)